Stockholder's Equity | Stockholder's Equity (a) Stock Equity and Incentive Plan The Company recognizes stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation-Stock Compensation . On June 8, 2022, at the Company's 2022 Annual Meeting of Stockholders, the stockholders of the Company approved an amendment and restatement of the Company’s current equity compensation plan to increase the number of shares of common stock reserved for issuance under the plan by 1,280 shares, from 4,800 shares to 6,080 shares (excluding rollover shares). Stock-based compensation expense was $566 and $701, excluding $12 and $4 of compensation charges related to our Amended and Restated 1996 Employee Stock Purchase Plan, or the ESPP, for the three months ended June 30, 2023 and 2022, respectively, and $850 and $1,560, excluding $24 and $26 of compensation shares related to ESPP, for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, there was $2,513 of total unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.80 years. As of June 30, 2023, there was $2,690 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 3.04 years. Stock Options During the three months ended June 30, 2023, the Company issued 147 shares of common stock upon the exercise of stock options and received $1,345 as payment for the exercise price. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the three months ended June 30, 2023, no stock options were granted and 261 stock options expired, were canceled or were forfeited. During the six months ended June 30, 2023, the Company issued 260 shares of common stock upon the exercise of stock options and received $2,367 as payment for the exercise price. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the six months ended June 30, 2023, 317 stock options were granted and 431 stock options expired, were canceled or were forfeited. During the six months ended June 30, 2022, 398 stock options were granted. The Company has historically estimated the fair value of each option grant on the date of grant using the Black-Scholes option-pricing model. The weighted average assumptions utilized to determine the fair value of options granted during the six months ended June 30, 2023 and 2022 are as follows: Six Months Ended June 30, 2023 2022 Risk-free interest rate 4.49 % 2.97 % Expected volatility 43.93 % 43.16 % Expected life (in years) 4.30 4.24 Dividend yield 0 % 0 % As of June 30, 2023, there were 1,377 options outstanding with a weighted average exercise price of $9.55 per share and 565 options exercisable with a weighted average exercise price of $9.63 per share. Restricted Stock During the three months ended June 30, 2023, no shares of restricted stock were granted and 3 shares of restricted stock were forfeited. Additionally, during the three months ended June 30, 2023, 51 shares of restricted stock vested, of which no shares of common stock were surrendered to the Company as payment by employees in lieu of cash to satisfy minimum tax withholding obligations in connection with the vesting of restricted stock. During the six months ended June 30, 2023, 151 shares of restricted stock were granted with a weighted average grant date fair value of $9.81 per share and 72 shares of restricted stock were forfeited. Additionally, during the six months ended June 30, 2023, 94 shares of restricted stock vested, of which no shares of common stock were surrendered to the Company as payment by employees in lieu of cash to satisfy minimum tax withholding obligations in connection with the vesting of restricted stock. As of June 30, 2023, the Company had no unvested outstanding options and no outstanding shares of restricted stock that were subject to performance-based or market-based vesting conditions. Common Stock Repurchase In the first quarter of 2023, the Company’s Board of Directors authorized the repurchase of a portion of executive common stock. The Company repurchased 23 shares of common stock held by executives at the Company to satisfy minimum tax withholding obligations in lieu of cash payment. No shares of common stock were repurchased during the twelve months ended December 31, 2022. (b) Employee Stock Purchase Plan The Company's ESPP affords eligible employees the right to purchase common stock, via payroll deductions, through various offering periods at a purchase price equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. During the three months ended June 30, 2023 and 2022, no shares were issued under the ESPP plan. During the six months ended June 30, 2023 and 2022, 0 and 22 shares were issued under the ESPP plan, respectively. The Company recorded compensation charges related to the ESPP of $12 and $4 for the three months ended June 30, 2023 and 2022, respectively, and $24 and $26 for the six months ended June 30, 2023 and 2022, respectively. (c) Stock-Based Compensation Expense The following table presents stock-based compensation expense, including expense for the ESPP, in the Company's consolidated statements of operations for the three and six months ended June 30, 2023 and 2022: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of product sales $ 9 $ 61 $ 16 $ 135 Cost of service sales 5 3 9 5 Research and development 149 190 237 331 Sales, marketing and support 59 25 97 211 General and administrative 356 426 515 904 $ 578 $ 705 $ 874 $ 1,586 (d) Accumulated Other Comprehensive Loss (AOCL) Comprehensive income (loss) includes net income (loss), unrealized gains and losses from foreign currency translation, and unrealized gains and losses on available for sale marketable securities. The components of the Company’s comprehensive income (loss) and the effect on earnings for the periods presented are detailed in the accompanying consolidated statements of comprehensive income (loss). The balances for the three months ended June 30, 2023 and 2022 are as follows: Foreign Currency Translation Unrealized Gain (Loss) on Available for Sale Marketable Securities Total Accumulated Other Comprehensive Loss Balance, March 31, 2023 $ (4,030) $ 1 $ (4,029) Other comprehensive income (loss) 75 (1) 74 Net other comprehensive income (loss) 75 (1) 74 Balance, June 30, 2023 $ (3,955) $ — $ (3,955) Foreign Currency Translation Total Accumulated Other Comprehensive Loss Balance, March 31, 2022 $ (3,602) $ (3,602) Other comprehensive loss (419) (419) Net other comprehensive loss (419) (419) Balance, June 30, 2022 $ (4,021) $ (4,021) The balances for the six months ended June 30, 2023 and 2022 are as follows: Foreign Currency Translation Unrealized (Loss) Gain on Available for Sale Marketable Securities Total Accumulated Other Comprehensive Loss Balance, December 31, 2022 $ (4,098) $ (12) $ (4,110) Other comprehensive income 143 12 155 Net other comprehensive income 143 12 155 Balance, June 30, 2023 $ (3,955) $ — $ (3,955) Foreign Currency Translation Total Accumulated Other Comprehensive Loss Balance, December 31, 2021 $ (3,409) $ (3,409) Other comprehensive loss (612) (612) Net other comprehensive loss (612) (612) Balance, June 30, 2022 $ (4,021) $ (4,021) |